Literature DB >> 34698396

Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis.

Zikou Liu1,2, Laura F Dagley1,2, Kristy Shield-Artin1,2, Samuel N Young1, Aleksandra Bankovacki1,3, Xiangyi Wang1,2, Michelle Tang4,5, Jason Howitt4,5, Che A Stafford6, Ueli Nachbur1,2, Cheree Fitzgibbon1, Sarah E Garnish1,2, Andrew I Webb1,2, David Komander1,2, James M Murphy1,2, Joanne M Hildebrand1,2, John Silke1,2.   

Abstract

Mixed lineage kinase domain-like (MLKL) is the executioner in the caspase-independent form of programmed cell death called necroptosis. Receptor-interacting serine/threonine protein kinase 3 (RIPK3) phosphorylates MLKL, triggering MLKL oligomerization, membrane translocation and membrane disruption. MLKL also undergoes ubiquitylation during necroptosis, yet neither the mechanism nor the significance of this event has been demonstrated. Here, we show that necroptosis-specific multi-mono-ubiquitylation of MLKL occurs following its activation and oligomerization. Ubiquitylated MLKL accumulates in a digitonin-insoluble cell fraction comprising organellar and plasma membranes and protein aggregates. Appearance of this ubiquitylated MLKL form can be reduced by expression of a plasma membrane-located deubiquitylating enzyme. Oligomerization-induced MLKL ubiquitylation occurs on at least four separate lysine residues and correlates with its proteasome- and lysosome-dependent turnover. Using a MLKL-DUB fusion strategy, we show that constitutive removal of ubiquitin from MLKL licences MLKL auto-activation independent of necroptosis signalling in mouse and human cells. Therefore, in addition to the role of ubiquitylation in the kinetic regulation of MLKL-induced death following an exogenous necroptotic stimulus, it also contributes to restraining basal levels of activated MLKL to avoid unwanted cell death.
© 2021 The Authors.

Entities:  

Keywords:  DUB-fusion; MLKL; membranes; necroptosis; ubiquitylation

Mesh:

Substances:

Year:  2021        PMID: 34698396      PMCID: PMC8634140          DOI: 10.15252/embj.2019103718

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  75 in total

1.  MLKL Requires the Inositol Phosphate Code to Execute Necroptosis.

Authors:  Cole M Dovey; Jonathan Diep; Bradley P Clarke; Andrew T Hale; Dan E McNamara; Hongyan Guo; Nathaniel W Brown; Jennifer Yinuo Cao; Christy R Grace; Peter J Gough; John Bertin; Scott J Dixon; Dorothea Fiedler; Edward S Mocarski; William J Kaiser; Tudor Moldoveanu; John D York; Jan E Carette
Journal:  Mol Cell       Date:  2018-06-07       Impact factor: 17.970

2.  The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways.

Authors:  Zhigao Wang; Hui Jiang; She Chen; Fenghe Du; Xiaodong Wang
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

3.  Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3.

Authors:  Xiaoqing Sun; Jianping Yin; Melissa A Starovasnik; Wayne J Fairbrother; Vishva M Dixit
Journal:  J Biol Chem       Date:  2001-12-04       Impact factor: 5.157

4.  Evolutionary divergence of the necroptosis effector MLKL.

Authors:  M C Tanzer; I Matti; J M Hildebrand; S N Young; A Wardak; A Tripaydonis; E J Petrie; A L Mildenhall; D L Vaux; J E Vince; P E Czabotar; J Silke; J M Murphy
Journal:  Cell Death Differ       Date:  2016-02-12       Impact factor: 15.828

5.  Polyubiquitin binding and cross-reactivity in the USP domain deubiquitinase USP21.

Authors:  Yu Ye; Masato Akutsu; Francisca Reyes-Turcu; Radoslav I Enchev; Keith D Wilkinson; David Komander
Journal:  EMBO Rep       Date:  2011-03-11       Impact factor: 8.807

6.  Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation.

Authors:  Fuminori Tokunaga; Shin-ichi Sakata; Yasushi Saeki; Yoshinori Satomi; Takayoshi Kirisako; Kiyoko Kamei; Tomoko Nakagawa; Michiko Kato; Shigeo Murata; Shoji Yamaoka; Masahiro Yamamoto; Shizuo Akira; Toshifumi Takao; Keiji Tanaka; Kazuhiro Iwai
Journal:  Nat Cell Biol       Date:  2009-01-11       Impact factor: 28.824

7.  Deubiquitinase-based analysis of ubiquitin chain architecture using Ubiquitin Chain Restriction (UbiCRest).

Authors:  Manuela K Hospenthal; Tycho E T Mevissen; David Komander
Journal:  Nat Protoc       Date:  2015-01-29       Impact factor: 13.491

8.  Phosphatidylserine externalization, "necroptotic bodies" release, and phagocytosis during necroptosis.

Authors:  Sefi Zargarian; Inbar Shlomovitz; Ziv Erlich; Aria Hourizadeh; Yifat Ofir-Birin; Ben A Croker; Neta Regev-Rudzki; Liat Edry-Botzer; Motti Gerlic
Journal:  PLoS Biol       Date:  2017-06-26       Impact factor: 8.029

Review 9.  Ubiquitin modifications.

Authors:  Kirby N Swatek; David Komander
Journal:  Cell Res       Date:  2016-03-25       Impact factor: 25.617

10.  HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death.

Authors:  A V Jacobsen; K N Lowes; M C Tanzer; I S Lucet; J M Hildebrand; E J Petrie; M F van Delft; Z Liu; S A Conos; J-G Zhang; D C S Huang; J Silke; G Lessene; J M Murphy
Journal:  Cell Death Dis       Date:  2016-01-14       Impact factor: 8.469

View more
  11 in total

Review 1.  The regulation of necroptosis by ubiquitylation.

Authors:  Yiliang Chen; Wenqing Ren; Qingsong Wang; Yuan He; Dan Ma; Zhenyu Cai
Journal:  Apoptosis       Date:  2022-08-08       Impact factor: 5.561

Review 2.  Deubiquitinases in cell death and inflammation.

Authors:  Kim Newton; Alexander D Gitlin
Journal:  Biochem J       Date:  2022-05-27       Impact factor: 3.766

3.  MLKL ubiquitylation: more than a makeover.

Authors:  Weihong Wang; Yi-Nan Gong
Journal:  Cell Death Differ       Date:  2022-01-12       Impact factor: 12.067

4.  The RHIM of the Immune Adaptor Protein TRIF Forms Hybrid Amyloids with Other Necroptosis-Associated Proteins.

Authors:  Max O D G Baker; Nirukshan Shanmugam; Chi L L Pham; Sarah R Ball; Emma Sierecki; Yann Gambin; Megan Steain; Margaret Sunde
Journal:  Molecules       Date:  2022-05-24       Impact factor: 4.927

5.  Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis.

Authors:  Zikou Liu; Laura F Dagley; Kristy Shield-Artin; Samuel N Young; Aleksandra Bankovacki; Xiangyi Wang; Michelle Tang; Jason Howitt; Che A Stafford; Ueli Nachbur; Cheree Fitzgibbon; Sarah E Garnish; Andrew I Webb; David Komander; James M Murphy; Joanne M Hildebrand; John Silke
Journal:  EMBO J       Date:  2021-10-26       Impact factor: 11.598

6.  The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL.

Authors:  Annette V Jacobsen; Catia L Pierotti; Kym N Lowes; Amanda E Au; Ying Zhang; Nima Etemadi; Cheree Fitzgibbon; Wilhelmus J A Kersten; André L Samson; Mark F van Delft; David C S Huang; Hélène Jousset Sabroux; Guillaume Lessene; John Silke; James M Murphy
Journal:  Cell Death Dis       Date:  2022-04-01       Impact factor: 9.685

7.  A proteomic perspective on TNF-mediated signalling and cell death.

Authors:  Maria C Tanzer
Journal:  Biochem Soc Trans       Date:  2022-02-28       Impact factor: 4.919

Review 8.  Rare catastrophes and evolutionary legacies: human germline gene variants in MLKL and the necroptosis signalling pathway.

Authors:  Sarah E Garnish; Joanne M Hildebrand
Journal:  Biochem Soc Trans       Date:  2022-02-28       Impact factor: 4.919

9.  Ubiquitylation of RIPK3 beyond-the-RHIM can limit RIPK3 activity and cell death.

Authors:  Daniel Frank; Sarah E Garnish; Jarrod J Sandow; Ashley Weir; Lin Liu; Elise Clayer; Lizeth Meza; Maryam Rashidi; Simon A Cobbold; Simon R Scutts; Marcel Doerflinger; Holly Anderton; Kate E Lawlor; Najoua Lalaoui; Andrew J Kueh; Vik Ven Eng; Rebecca L Ambrose; Marco J Herold; Andre L Samson; Rebecca Feltham; James M Murphy; Gregor Ebert; Jaclyn S Pearson; James E Vince
Journal:  iScience       Date:  2022-06-17

Review 10.  Insights Into the Properties, Biological Functions, and Regulation of USP21.

Authors:  Tao An; Yanting Lu; Xu Yan; Jingjing Hou
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.